Coherus BioSciences (NASDAQ:CHRS) Issues Earnings Results

Coherus BioSciences (NASDAQ:CHRS) released its quarterly earnings data on Monday. The biotechnology company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10), Zacks reports.

Coherus BioSciences Price Performance

Shares of NASDAQ CHRS traded up $0.05 during mid-day trading on Monday, hitting $1.02. 1,964,131 shares of the stock traded hands, compared to its average volume of 2,711,647. The company has a market cap of $118.24 million, a PE ratio of -12.75 and a beta of 1.01. Coherus BioSciences has a twelve month low of $0.66 and a twelve month high of $2.43. The firm has a 50 day simple moving average of $0.95 and a two-hundred day simple moving average of $1.13.

Analyst Ratings Changes

CHRS has been the subject of a number of recent research reports. StockNews.com downgraded Coherus BioSciences from a “hold” rating to a “sell” rating in a research report on Friday. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Coherus BioSciences in a research note on Tuesday, April 29th. Finally, UBS Group reaffirmed a “neutral” rating and set a $1.05 price objective (down from $1.50) on shares of Coherus BioSciences in a research report on Thursday, April 24th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $5.26.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.